publication date: May. 3, 2019
Conversation with The Cancer Letter
Hirsch: Syapse collaboration with Amgen will focus on real world evidence and hematologic malignancies
President and founder, Syapse
Syapse, a precision medicine company with a data sharing network, has announced a collaboration with Amgen to use analytics and real world evidence to support drug development.
“Amgen has a substantial track record and a robust portfolio in the hematologic malignancy space, and this is something that we look forward to advancing with them,” said Jonathan Hirsch, president and founder of Syapse. “To speak specifically about observational research, we’re collaborating with Amgen to develop certain analytical methodologies that can be used for observational research on specific tumor types and areas of unmet clinical need.”
This is Syapse’s second publicly disclosed collaboration with a pharmaceutical company. In January 2018, Syapse teamed up with Roche to develop software for measuring health outcomes and the economic impact of precision medicine (The Cancer Letter, Jan. 12, 2018).
The collaboration will also focus on identifying patients within the Syapse Learning Health Network who could be eligible for Amgen-sponsored clinical trials, and seek to bring these trials to community health system sites.
“What’s really different about what we’re doing is the depth of the partnership that we’re engaging in with Amgen,” Hirsch said. “We deeply partner to understand Amgen’s business objectives, align those with the … Continue reading Hirsch: Syapse collaboration with Amgen will focus on real world evidence and hematologic malignancies
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.